Analysis Reports - TradeFomo

Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

All AAOI ABUS ABVX ACAD ACRV ADMA AGIO ALMS ALMU ALTS APGE ARTV ASX AUPH AVAV AXTI BCRX CAI CAKE CEG CELC CEP CGON CIEN CNC COGT CRCL CTMX CTRI GCT GLW GOOG GPCR HALO HIMS HOOD HWM IDYA IREN IVVD KALA KALV KRYS LENZ LEVI LITE LQDA LRMR LULU LUNR MDGL MESO MIRM MOH MPWR MRVL MTCH MU MVST NBIS NKE NRIX NVAX OKUR OLMA ONC ORKA OSCR PHAT POET PRLD PYG RBLX RDDT RIGL RKLB SGHC SPRY SRPT TARS TBPH TH TRVI TSHA UNH VEON VOR WVE XFOR ZBIO ZLAB ZYME

Novavax is undervalued. It holds $751M cash, has profitable licensing deals for its Matrix-M tech, and faces activist pressure to unlock shareholder value. The market ignores this shift.

The Matrix-M Mirage: Why the Market is Mispricing Novavax's Sum-of-the-Parts

2026-04-09BullishStrongChange from report: +7.8%1M: +11.2%

Novavax is undervalued. It holds $751M cash, has profitable licensing deals for its Matrix-M tech, and faces activist pressure to unlock shareholder value. The market ignores this shift.